BioRestorative Therapies, Inc.

https://www.biorestorative.com

BioRestorative Therapies, Inc. is a biotechnology company focused on the research, development, and commercialization of cellular therapies, primarily utilizing adult stem cells. Headquartered in Melville, New York, the company's mission is to develop innovative stem cell-based treatments to address unmet medical needs in patients suffering from highly prevalent conditions. Founded in 1997, the company was formerly known as Stem Cell Assurance, Inc. before changing its name in August 2011.

BioRestorative Therapies operates with two core clinical development programs and a commercial platform. Its Disc/Spine Program features BRTX-100, an autologous cultured mesenchymal stem cell therapy designed for the non-surgical treatment of painful lumbosacral disc disorders, specifically chronic lumbar disc disease (cLDD). The ThermoStem® program focuses on metabolic disorders, including obesity and Type 2 Diabetes, using brown adipose-derived stem cells. Additionally, the company has a commercial BioCosmeceutical platform exploring aesthetic medicine applications, including a proprietary serum for fine lines and wrinkles.

Under the leadership of CEO Lance Alstodt, BioRestorative Therapies has achieved several recent milestones. In February 2026, the company completed enrollment for its Phase 2 clinical trial of BRTX-100 for cLDD, and subsequently reported positive blinded data in March 2026, demonstrating meaningful improvements in pain and function. The company also announced a strategic collaboration in April 2026 to advance its BioCosmeceutical platform. In October 2025, the Japanese Patent Office issued a Notice of Allowance for the ThermoStem® platform, providing broad intellectual property protection for its technology.

Latest updates

BioRestorative Data Presentation Signals Progress in Disc Disease Therapy

Event summary

  • BioRestorative Therapies will present Phase 2 clinical safety and efficacy data for BRTX-100, its mesenchymal stem cell therapy for chronic lumbar disc disease, at the ISCT 2026 conference in Dublin.
  • A separate presentation will detail preclinical data on the company’s exosome platform, focusing on therapeutic and cosmetic applications.
  • Francisco Silva, Founder and Chief Scientist, will present the disc disease data on May 6, 2026, while Michael Joyce, Director of Research and Development, will cover the exosome platform.
  • BRTX-100 is intended for non-surgical treatment of painful lumbosacral disc disorders and utilizes a proprietary cell culturing process.

The big picture

BioRestorative’s focus on stem cell therapies for degenerative disc disease represents a niche within the broader regenerative medicine market, which is attracting increasing investment. The company’s dual focus on therapeutic applications and bioceuticals suggests an attempt to broaden its revenue base and mitigate risk, but success hinges on demonstrating clinical efficacy and navigating regulatory hurdles in both areas. The ISCT presentation provides a key data point for assessing the progress of its lead program.

What we're watching

Clinical Efficacy
The Phase 2 data presentation will be critical in assessing the viability of BRTX-100; positive results could accelerate regulatory pathways, while negative findings would likely impact investor sentiment.
Exosome Platform
How BioRestorative leverages its exosome platform for both therapeutic and cosmetic applications will determine its ability to diversify revenue streams beyond its core disc disease program.
Regulatory Landscape
The company's stated intention to pursue FDA approvals in the BioCosmeceuticals space indicates a potential shift in strategy, and the success of this effort will depend on navigating evolving regulatory frameworks.

BioRestorative Gains Validation Boost with Key Opinion Leader Partnership

Event summary

  • BioRestorative Therapies has partnered with Dr. David J. Goldberg, a leading dermatologist and researcher, to lead clinical evaluations of its BioCosmeceutical platform.
  • The collaboration aims to generate comparative outcome data against existing aesthetic treatments, expected to be published and support broader commercial adoption.
  • Dr. Goldberg will also present study findings at industry conferences, expanding awareness and reinforcing BioRestorative's positioning.
  • The partnership is part of a three-pillar strategy including manufacturing, commercial execution (with 203 Creates), and now clinical validation.

The big picture

BioRestorative’s partnership with Dr. Goldberg represents a strategic shift towards data-driven validation in the rapidly growing regenerative aesthetics market. This move addresses a key challenge for emerging regenerative therapies – establishing clinical efficacy and gaining physician trust. The collaboration aims to position BioRestorative as a credible player in a market increasingly demanding scientific evidence for cosmetic and therapeutic claims, potentially differentiating it from competitors relying solely on anecdotal evidence.

What we're watching

Clinical Outcomes
The success of the clinical trial led by Dr. Goldberg will be critical in validating BioRestorative’s BioCosmeceutical platform and influencing physician adoption, and the results will be closely scrutinized by investors.
Commercial Execution
Whether 203 Creates can effectively translate the clinical data into a compelling brand and go-to-market strategy will determine the speed of commercial expansion and overall revenue generation.
KOL Influence
The extent to which Dr. Goldberg’s influence can drive adoption within physician networks and industry forums will be a key indicator of the partnership’s long-term value.

BioRestorative Outsources Brand Building in Biocosmeceutical Push

Event summary

  • BioRestorative Therapies has partnered with 203 Creates, a brand strategy and marketing agency, to develop and commercialize its biocosmeceutical platform.
  • 203 Creates will lead the development of brand architecture, digital infrastructure, and go-to-market execution for BioRestorative’s BioX™ product line.
  • The collaboration aims to accelerate BioRestorative’s time to market and establish a differentiated presence in the biocosmeceutical category.
  • BioRestorative’s biocosmeceutical platform incorporates biologically active formulations, including extracellular vesicles and regenerative ingredients, targeting skin health and hair vitality.

The big picture

BioRestorative’s move to outsource brand building signals a recognition of the challenges in commercializing science-backed skincare. The biocosmeceutical market is emerging, blending the precision of biotechnology with the consumer appeal of premium skincare, a space where brand perception is often more critical than scientific validation. This partnership represents a bet on 203 Creates’ expertise to bridge this gap and establish BioRestorative as a credible player in a competitive landscape.

What we're watching

Brand Adoption
The success of this partnership hinges on 203 Creates’ ability to translate BioRestorative’s complex science into a compelling consumer brand, a challenge given the nascent nature of the biocosmeceutical market.
Regulatory Boundaries
BioRestorative will need to carefully navigate regulatory constraints while communicating the scientific basis of its products, potentially limiting marketing claims and slowing adoption.
Channel Strategy
The effectiveness of BioRestorative’s planned direct-to-consumer, physician partnership, and global distribution channels will determine the platform’s scalability and long-term profitability.

BioRestorative's BRTX-100 Phase 2 Data Bolsters Disc Disease Therapy Prospects

Event summary

  • BioRestorative Therapies’ Phase 2 trial for BRTX-100 demonstrated improvements in pain and function in patients with chronic lumbar disc disease, with over 50% reporting >50% improvement in key measures.
  • Data, presented at the 2026 Orthopaedic Research Society Annual Meeting, showed sustained improvements out to 104 weeks in a subset of patients.
  • The company achieved alignment with the FDA regarding Phase 3 trial design, including endpoints and statistical powering.
  • The Phase 2 study efficacy endpoint is a greater than a 30% improvement in both the Visual Analog Scale (VAS) and Oswestry Disability Index (ODI) at 52 weeks.

The big picture

Chronic lower back pain represents a multi-billion dollar market with limited non-surgical therapeutic options. BioRestorative’s BRTX-100, if successful, could offer a significant alternative to surgery or chronic pain medication, potentially disrupting the existing treatment paradigm. The FDA alignment accelerates the development timeline, but the Phase 3 trial will be a crucial inflection point for the company’s valuation.

What we're watching

Regulatory Pathway
The FDA’s confirmation of the Phase 3 framework is a positive signal, but the agency’s ultimate approval will hinge on the trial’s success and potential safety concerns that may arise.
Clinical Efficacy
Sustained efficacy beyond the 52-week mark, as indicated by the longer-term follow-up data, will be critical to demonstrating long-term clinical benefit and driving adoption.
Commercialization
BioRestorative’s ability to efficiently manufacture BRTX-100 and establish a physician network for administration will be key to successful commercialization, given the specialized nature of the treatment.

BioRestorative Phase 2 Data Boosts BRTX-100 Prospects, FDA Alignment Signals Path to Phase 3

Event summary

  • BioRestorative Therapies will present blinded Phase 2 data on BRTX-100, its stem cell therapy for chronic lumbar disc disease, on March 28, 2026, at the Orthopaedic Research Society Annual Meeting.
  • The data covers approximately 45 patients and focuses on pain, function, and safety/tolerability.
  • BioRestorative has achieved alignment with the FDA on key elements of a future Phase 3 clinical trial for BRTX-100, including endpoints and dosing strategy.
  • The FDA did not raise safety concerns and confirmed the appropriateness of BioRestorative’s manufacturing process (CMC framework).

The big picture

BioRestorative’s progress with BRTX-100 represents a potential shift towards regenerative therapies for chronic lower back pain, a condition affecting millions and costing the healthcare system billions annually. The FDA alignment significantly de-risks the development pathway, but the company faces the challenge of demonstrating robust efficacy and navigating a competitive landscape dominated by established pain management solutions. The company's broader portfolio, including ThermoStem® and BioCosmeceuticals, adds diversification but also complexity to its overall strategy.

What we're watching

Clinical Efficacy
The upcoming data presentation will be critical in assessing the true clinical benefit of BRTX-100, as the reported improvements must be statistically significant and clinically meaningful to support Phase 3 progression.
Regulatory Risk
While the FDA alignment is positive, the final IND application review remains a potential hurdle, and any unexpected requests or concerns could delay or alter the Phase 3 trial design.
Commercialization
The success of BRTX-100 hinges on its ability to offer a compelling non-surgical alternative for chronic lower back pain, a market with significant unmet need but also intense competition from existing treatments.

BioRestorative Aims to Disrupt Aesthetics with Regenerative Skincare at Be+Well Show

Event summary

  • BioRestorative Therapies will participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026.
  • The show attracts over 35,000 beauty and wellness professionals and 600 exhibiting brands.
  • Crystal Romano, Head of Global Commercial Operations, will lead BioRestorative’s engagement.
  • BioRestorative is leveraging its cell-based secretome technology to enter the aesthetics and longevity markets.

The big picture

BioRestorative is attempting to disrupt the $500+ billion global beauty and personal care market by applying regenerative medicine technology, a strategy that positions them against established brands with significant marketing budgets. Their focus on a vertically integrated, cGMP-compliant manufacturing process differentiates them, but also introduces operational complexity. The company’s success will depend on convincing practitioners and consumers that biologically active ingredients offer a superior, albeit premium, alternative to traditional cosmetic treatments.

What we're watching

Market Adoption
The success of BioRestorative’s strategy hinges on the continued adoption of exosome treatments and regenerative skincare by clinics and medspas, which may be influenced by evolving consumer preferences and clinical data.
Regulatory Landscape
The company’s ambition to pioneer FDA approvals in the biocosmeceuticals space will be heavily influenced by the FDA’s evolving regulatory framework for cell-based products and biologics, potentially creating hurdles or accelerating pathways.
Manufacturing Scale
BioRestorative’s vertically integrated manufacturing model, while providing a competitive advantage, will need to demonstrate scalability and cost-effectiveness to support broader commercialization and maintain premium pricing.

BioRestorative Advances Spine Therapy, Eyes Regulatory Clarity and Commercial Expansion

Event summary

  • BioRestorative Therapies completed enrollment in its Phase 2 trial for BRTX-100, its therapy for chronic lumbar disc disease, with 99 patients across 15 U.S. sites.
  • The company received a positive Type B regulatory outcome from the FDA regarding its Phase 3 trial design and endpoints.
  • BioRestorative raised $5 million via a public offering to strengthen its balance sheet.
  • The company is accelerating its BioCosmeceutical strategy, leveraging its cell-based secretome platform.
  • Patent allowance was granted in Australia for the ThermoStem® metabolic platform, covering three-dimensional brown adipose-derived stem cell aggregates.

The big picture

BioRestorative's progress hinges on successfully navigating the stringent regulatory landscape for cell therapies, particularly in spine medicine. The company's dual focus on BRTX-100 and the ThermoStem® platform represents a bet on the growing demand for regenerative therapies, while the BioCosmeceutical strategy aims to provide near-term revenue and brand validation. The $5 million raise provides a short-term runway, but the company will likely need to secure additional funding or partnerships to support Phase 3 development.

What we're watching

Clinical Execution
The topline Phase 2 data release in early 2027 will be critical; a failure to demonstrate efficacy could significantly impact the company's valuation and future development plans.
Regulatory Pathway
The FDA's feedback on the Phase 3 IND amendment submission in 2H 2026 will reveal the extent of remaining regulatory hurdles and potential for accelerated approval.
Commercial Traction
The success of the BioCosmeceutical platform in generating non-dilutive revenue will be key to supporting ongoing development and mitigating burn, and its ability to scale beyond initial adoption will be a crucial indicator.

BioRestorative Bolsters ThermoStem Patent Protection in Australia

Event summary

  • BioRestorative Therapies secured patent allowance No. 2020265664 from IP Australia.
  • The patent covers a method for creating 3D brown adipose-derived stem cell aggregates (BADSC) for ThermoStem®.
  • The patent provides broad protection for BioRestorative’s allogeneic, off-the-shelf ThermoStem® technology.
  • The allowance strengthens BioRestorative’s IP portfolio in the obesity and metabolic disorders space.
  • The company aims to develop ThermoStem® as a cell-based alternative to GLP-1 drugs.

The big picture

BioRestorative is attempting to carve out a niche in the rapidly expanding obesity and metabolic disorder treatment market, currently dominated by GLP-1 receptor agonists. The company’s ThermoStem® technology represents a bet on cell-based therapies as a potentially safer and longer-lasting alternative, but faces significant hurdles in clinical development and commercialization against a backdrop of intense competition and high patient expectations. Securing this Australian patent is a tactical win, but doesn't guarantee success.

What we're watching

Commercialization
The success of ThermoStem® hinges on demonstrating clinical efficacy and safety in human trials, a process that could take several years and require significant investment.
GLP-1 Competition
The GLP-1 market is dominated by established players; BioRestorative must prove ThermoStem® offers a compelling advantage – longer duration, improved safety – to gain meaningful market share.
IP Defense
While this Australian patent strengthens BioRestorative’s position, ongoing patent challenges and potential infringement suits from competitors remain a risk to their competitive advantage.

BioRestorative Receives FDA Nod for Accelerated Disc Disease Therapy Pathway

Event summary

  • BioRestorative Therapies received positive feedback from the FDA regarding a potential accelerated Biologics License Application (BLA) pathway for BRTX-100, a treatment for chronic lumbar disc disease (cLDD).
  • The FDA endorsed the proposed Phase 3 study design, sample size, and powering assumptions, pending review of the Phase 3 Investigational New Drug (IND) application.
  • BioRestorative plans to submit the Phase 3 IND application in the second half of 2026, initiating Phase 3 enabling activities.
  • The Fast Track Designation, granted in February 2025, aims to expedite the review process and potentially allow for Priority Review and Accelerated BLA Approval.

The big picture

The positive FDA feedback represents a significant de-risking event for BioRestorative, potentially accelerating the timeline for a novel treatment for chronic lumbar disc disease, a condition affecting a substantial portion of the adult population and imposing a significant economic burden. The Fast Track designation and potential for accelerated approval highlight the unmet medical need and the potential for a lucrative market if BRTX-100 proves effective. However, the company's success hinges on navigating the remaining regulatory and clinical milestones.

What we're watching

Regulatory Risk
The FDA’s final review of the Phase 3 IND application remains a critical hurdle, and any unexpected concerns could delay or alter the development pathway.
Clinical Efficacy
The ongoing Phase 2 trial’s efficacy data will be scrutinized, as the Phase 3 design is predicated on the current upward trend, and a reversal could jeopardize the program.
Execution Timeline
BioRestorative’s ability to execute Phase 3 enabling activities and submit the IND application by the anticipated timeframe in 2H 2026 will be key to maintaining momentum and investor confidence.

BioRestorative Enrolls Final Patients in Landmark Disc Disease Trial

Event summary

  • BioRestorative Therapies has completed patient enrollment in its Phase 2 clinical trial of BRTX-100 for chronic lumbar disc disease.
  • The trial enrolled 99 participants in a randomized, double-blind, sham-controlled design across 15 U.S. clinical sites.
  • The study is described as the largest FDA-authorized Phase 2 cell therapy trial for chronic lumbar disc disease.
  • The trial's primary endpoints focus on safety (adverse events) and efficacy (ODI and VAS improvements).

The big picture

The trial represents a significant effort to address a large and costly healthcare problem – chronic lower back pain, which affects a substantial portion of the adult population and carries a significant economic burden. BioRestorative's approach, utilizing autologous mesenchymal stem cells, aims to target the underlying disc degeneration, a departure from current symptomatic treatments. The trial's scale and rigorous design, if successful, could establish a new standard for cell therapy interventions in spine medicine.

What we're watching

Regulatory Pathway
The FDA's feedback on the trial data will be critical in determining the likelihood of Phase 3 approval and a Biologics License Application (BLA) submission, and the company's stated confidence should be viewed with caution.
Efficacy Data
The actual efficacy results, particularly the ODI and VAS improvements, will dictate investor sentiment and the potential for commercial success, given the high bar for therapeutic intervention in chronic back pain.
Execution Risk
The accelerated site productivity observed in the last six months needs to be sustained throughout the trial and into any subsequent Phase 3 studies to maintain timelines and manage costs.
CID: 487